Haemophilia A
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 26 trials with date data
Clinical Trials (26)
Total enrollment: 5,041 patients across 26 trials
Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
BAY81-8973 Pediatric Safety and Efficacy Trial
A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.
An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.
An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men
A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)
Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
Register of Patients With haEmophilia A tReated With Afstyla®
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients
Related Jobs
Rare Disease Hemophilia Account Specialist - Chicago
Patient Value Partner Hematology
Internship in Innovation & Sustainability - For students in the field of Digital Health, Health Informatics, Biomedical Engineering, Healthcare IT, or Computer Science
Patient Journey Partner (field-based HCP point of contact - Hemophilia)
Senior SW Engineer
Senior Scientist, Translational Medicine Oncology (Hematology)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.